港股異動 | 創陞控股再升13%創新高 9日累計飆升近140%
格隆匯1月6日丨創陞控股(2680.HK)近期公司股價持續拉昇,目前已經累計上漲9日大漲近140%,股價持續創新高。現漲13.19%,報5.15港元,暫成交6600萬港元,最新總市值20.6億港元。

日前公司公佈,擬透過一間附屬公司在公開市場收購合共260.8萬股台州水務(相當於該公司總股本的5.22%),總代價約為1098.1萬元.考慮到台州水務之財務表現不斷改善,公司認為收購台州水務H股為具吸引力之投資,可提升公司之投資回報。
值得注意的是,公司中期業績由盈轉虧至232.4萬港元,員工成本以及行政及經營開支增加所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.